Skip to content
← Index board

Health Optimization Index

Methylene Blue

Nick’s assessment
Promising
Research evidence
B, good evidence
Attention
16.4 / 100▲ Rising this week
6.1/ 10

BioHarmony score

Methylene blue scores 6.0–6.5/10: strong as an FDA-approved methemoglobinemia antidote and an acute mitochondrial redox tool, but healthy-user nootropic evidence is still thin despite human fMRI signals from Rodriguez 2016.

Read the full report Benefits, risks and practical guidance.

Read Nick’s assessment Why it earned this rating

Methylene Blue is a 6.0–6.5/10 fit for advanced users who understand that methylene blue is a drug-like redox compound, not a casual blue nootropic, because the strongest evidence is medical, while healthy-user cognition claims remain much thinner. Rothenberg 2025 gives the strongest anchor, while Rodriguez 2016 adds useful context without closing the case. The honest gap is simple: low-dose consumer protocols do not have the same backing as methemoglobinemia, shock, or procedure-specific uses. That puts Methylene Blue in the tracked-experiment category, not the automatic-staple category. In practice, Methylene Blue makes the most sense when you monitor dose, medication interactions, mood, sleep, cognition tasks, oxygenation context, and adverse effects and avoid treating Methylene Blue like a broad brain-energy upgrade.

✅ Best for: Adults with suspected mitochondrial dysfunction, chronic fatigue patterns, post-viral fatigue, or metabolic dysfunction who are not taking serotonergic drugs and can source pharmaceutical-grade methylene blue. Cognitively demanding knowledge workers who want an occasional 0.5-5 mg acute mental-clarity tool. Biohackers pairing low-dose methylene blue with red light therapy, while admitting the stack is not proven by large RCTs. Adults over 50 exploring mitochondrial support alongside creatine or NAD+ precursors. Medical use belongs to clinicians: acquired methemoglobinemia, select shock contexts, and procedure-specific local analgesia.

❌ Avoid if: You take SSRIs, SNRIs, MAOIs, serotonergic opioids, tramadol, dextromethorphan, linezolid, high-dose 5-HTP, or other serotonergic agents without clinician guidance. Avoid methylene blue with known or possible G6PD deficiency unless tested and cleared, especially with Mediterranean, African, Middle Eastern, or Southeast Asian ancestry. Avoid during pregnancy or planned pregnancy, severe renal impairment, phenothiazine hypersensitivity, and before surgery unless the care team knows. Also avoid aquarium-grade, dye-grade, or generic marketplace methylene blue. Source quality is not a minor detail here.

Share your experience

Your answers are optional and help other readers — they never change my score. How community input works.

Tried it in real life?

How would you assess it?

Favorable is the strongest rating, followed by Promising, then Experimental. Overhyped means the claims outrun the evidence or interest is fading.

Make a 12-month prediction Will it rise or fall in the Index?

Choose a direction and your confidence. Correct predictions earn leaderboard points.

Your 12-month call on Methylene Blue
How sure are you?

Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →

Updated Sep 21, 2026 How the Index ranks →

Educational information, not medical advice. Ask a qualified clinician about risks and interactions. Independent ratings: no affiliate links, sponsored placements or paid rankings.